This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Coming back to post #89, because the follow-up matters more than the original answer.
Allocation and rationing: during severe shortages, suppliers might ration allocation to prescribers. Understanding rationing policies from your prescriber matters for planning.
Compounding during shortages: some jurisdictions allow pharmacy compounding when a marketed product is in shortage. That permission is jurisdiction-specific and time-limited (usually for the duration of the shortage).
Supply interruptions: official shortage notices are published by regulatory agencies. That is the correct primary source rather than pharmacy rumors or forum discussion.
post #93 answers the question as asked. The question underneath it is different.
Resuming after a gap: after a gap of days or a few weeks, most people resume at the dose they were on when they stopped. Gaps of months might require retitration discussion with a clinician.
I read post #93 twice before replying, because I had assumed the opposite.
Shortage predictions: regulators and suppliers issue shortage alerts before they become acute. Checking the regulatory website for shortages gives you advance notice.
This follows post #93 rather than contradicting it.
Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.
Shortage predictions: regulators and suppliers issue shortage alerts before they become acute. Checking the regulatory website for shortages gives you advance notice.
Resuming after a gap: after a gap of days or a few weeks, most people resume at the dose they were on when they stopped. Gaps of months might require retitration discussion with a clinician.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
Picking up post #97: that is the part I would want checked first.
Managing an unplanned gap: if a shortage causes a gap in treatment, the questions are how long the gap will be and how that affects your condition. Discussing with your clinician is prudent if the gap is weeks or longer.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
Coming back to post #101, because the follow-up matters more than the original answer.
Supply interruptions: official shortage notices are published by regulatory agencies. That is the correct primary source rather than pharmacy rumors or forum discussion.
Picking up post #101: that is the part I would want checked first.
Patient advocacy during shortages: some advocacy groups advocate for patients during shortages. Knowing who they are and following their communication is useful.
I read post #105 twice before replying, because I had assumed the opposite.
International supply chains: a shortage in one country does not mean shortage in another. That is why ordering from multiple suppliers before a shortage gets bad is prudent if you can.
Allocation and rationing: during severe shortages, suppliers might ration allocation to prescribers. Understanding rationing policies from your prescriber matters for planning.
Picking up post #108: that is the part I would want checked first.
Compounding during shortages: some jurisdictions allow pharmacy compounding when a marketed product is in shortage. That permission is jurisdiction-specific and time-limited (usually for the duration of the shortage).
Coming back to post #110, because the follow-up matters more than the original answer.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
Managing an unplanned gap: if a shortage causes a gap in treatment, the questions are how long the gap will be and how that affects your condition. Discussing with your clinician is prudent if the gap is weeks or longer.
Dose hold versus tapering: if a temporary shortage forces a gap, holding your dose and resuming when supply returns is different from gradually tapering. The two are different decisions.
This follows post #112 rather than contradicting it.
International supply chains: a shortage in one country does not mean shortage in another. That is why ordering from multiple suppliers before a shortage gets bad is prudent if you can.
Communication from suppliers: a supplier having supply problems usually communicates them. If a supplier goes silent, that is itself information.
Worth separating two things that post #114 runs together.
Allocation and rationing: during severe shortages, suppliers might ration allocation to prescribers. Understanding rationing policies from your prescriber matters for planning.
Resuming after a gap: after a gap of days or a few weeks, most people resume at the dose they were on when they stopped. Gaps of months might require retitration discussion with a clinician.
Shortage predictions: regulators and suppliers issue shortage alerts before they become acute. Checking the regulatory website for shortages gives you advance notice.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Managing an unplanned gap in supply
Managing an unplanned gap in supply — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the answer.…
|
+105 | 110 | 5.1k | 3mo |
|
How shortages have affected compounding permissions — does this still hold?
How shortages have affected compounding permissions — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. A coverage question with the paperwork…
|
+27 | 31 | 21k | 17h |
|
Coming back to: Official shortage notices and what they authorise
Official shortage notices and what they authorise Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
|
+85 | 92 | 5.5k | 11mo |
|
Managing an unplanned gap in supply — what changed since
On the subject in the title: Managing an unplanned gap in supply — what changed since Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…
|
+114 | 124 | 54k | 8mo |
|
How shortages have affected compounding permissions
How shortages have affected compounding permissions I have a specific reason for asking rather than idle curiosity, and the context is below. A coverage question with the paperwork detail included, since that…
|
+61 | 71 | 3.6k | 2d |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Prior authorisation: what the criteria usually require
On the subject in the title: Prior authorisation: what the criteria usually require Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…
|
+9 | 13 | 3.2k | 17mo |
|
List price versus negotiated price versus what you pay
On the subject in the title: List price versus negotiated price versus what you pay Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires.…
|
+99 | 115 | 11k | 3mo |
|
External review after an internal denial
External review after an internal denial Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
|
2 | 18k | 1mo | |
|
Why a compound being unapproved is not the same as being illegal to possess
Why a compound being unapproved is not the same as being illegal to possess I have a specific reason for asking rather than idle curiosity, and the context is below. Structured report rather than an opinion,…
|
+72 | 78 | 23k | 3mo |
|
Peer-to-peer review: what actually happens on the call — one year on
Peer-to-peer review: what actually happens on the call — one year on — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in this…
|
+2 | 6 | 41k | 5mo |